Upgrading Your Aggregate Analysis of Viral Vectors with Novel Wide Pore SEC Columns

Adeno-associated viruses (AAVs), virus-like particles (VLPs), oligonucleotides, and lipid nanoparticles represent the next generation of biotherapeutics for cell and gene therapy, as well as vaccines. Characterizing these novel and challenging biotherapeutics requires advanced, capable, and robust technology. Novel 500 and 1,000 Å pore sizes provide suitability for samples of larger diameter, making them ideal for your aggregation analyses of ultralarge biomolecules (>1 MDa) such as AAVs and VLPs. Learn more about the reproducible, high-resolution separations possible with these robust new columns – and the time and cost savings that follow.

Topics include:

• Learn how to adapt your protein size-exclusion chromatography (SEC) method for larger biotherapeutics
• Discover the robust reproducibility of novel ultrawide pore SEC columns
• Learn how to improve your critical quality attribute (CQA) analysis or viral vector such as AAVs